Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury

Retrospective observational study. Data derived from two multinational ICU studies (Ruby and Sapphire). Critically ill patients with early stage 2-3 AKI. None. We analyzed three consecutive uCCL14 measurements at 12-hour intervals after diagnosis of stage 2-3 AKI by Kidney Disease Improving Global O...

Descripción completa

Detalles Bibliográficos
Autores: Prowle, John R., Artigas Raventós, Antoni|||0000-0002-8029-1017, Bagshaw, Sean M.|||0000-0003-3633-6596, Forni, Lui G., Heung, Michael, Hoste, Eric, Marlies, Ostermann, Koyner, Jay L., Chawla, Lakhmir S, Kampf, J. Patrick, Kwan, Thomas, McPherson, Paul, Kellum, John A.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:273051
Acceso en línea:https://ddd.uab.cat/record/273051
https://dx.doi.org/urn:doi:10.1097/CCE.0000000000000870
Access Level:acceso abierto
Palabra clave:Acute kidney injury
Biomarkers
C-C motif chemokine ligand 14
Critical illness
Prognosis
Descripción
Sumario:Retrospective observational study. Data derived from two multinational ICU studies (Ruby and Sapphire). Critically ill patients with early stage 2-3 AKI. None. We analyzed three consecutive uCCL14 measurements at 12-hour intervals after diagnosis of stage 2-3 AKI by Kidney Disease Improving Global Outcomes criteria. Primary outcome was persistent severe AKI, defined as 72 consecutive hours of stage 3 AKI, death, or receipt of dialysis prior to 72 hours. uCCL14 was measured using the NEPHROCLEAR uCCL14 Test on the Astute 140 Meter (Astute Medical, San Diego, CA). Based on predefined, validated cutoffs, we categorized uCCL14 as: low (≤ 1.3 ng/mL), medium (

Similares en LA Referencia